OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.

Also called NCT01955200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,724 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01955200
Other papers using this trial's data
  • Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)-2 Trial British journal of haematology, 2022-01 DOI, PubMed 34611892

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01955200. Randomized; no masking; primary purpose treatment. Start 2013-10-05 (actual); primary completion 2016-12-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
Acronym
OPTIMA-2
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Cilostazol
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Clopidogrel
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)
Collaborator
National Natural Science Foundation of China (class: other government)

Record details

Record id
cardio:ct-nct01955200
Content hash
32d93162830acff400b03c098bafc348c67eaeae702ca0d8c08d522c91dcf98c